Abstract
Plasma or serum protein binding determinations of extensively bound drugs are subject to serious error if the analytical methods employed do not discriminate between such drugs and their degradation products, metabolites, and impurities. Experimental evidence is presented to demonstrate the magnitude of this problem with respect to warfarin.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
G. Levy and A. Yacobi. Effect of plasma protein binding on the elimination of warfarin.J. Pharm. Sci. 63:805–806 (1974).
A. Yacobi and G. Levy. Comparative pharmacokinetics of coumarin anticoagulants. XIV. Relationship between protein binding, distribution, and elimination kinetics of warfarin in rats.J. Pharm. Sci. 64:1660–1664 (1975).
R. J. Lewis, L. P. Ilnicki, and M. Corlstrom. The assay of warfarin in plasma or stool.Biochem. Med. 4:376–382 (1970).
A. Yacobi, L. B. Wingard, Jr., and G. Levy. Comparative pharmacokinetics of coumarin anticoagulants. X. Relationship between distribution, elimination, and anticoagulant action of warfarin.J. Pharm. Sci. 63:868–872 (1974).
Author information
Authors and Affiliations
Additional information
Supported in part by Grant GM20852 from the National Institutes of Health.
This is paper XVI in the series “Comparative pharmacokinetics of coumarin anticoagulants.” Previous paper: A. Yacobi, C.-M. Lai, and G. Levy,J. Pharm. Sci. 64 (1975).
Rights and permissions
About this article
Cite this article
Yacobi, A., Levy, G. Importance of assay specificity for plasma protein binding determinations. Journal of Pharmacokinetics and Biopharmaceutics 3, 439–441 (1975). https://doi.org/10.1007/BF01059475
Received:
Revised:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF01059475